Replies to post #76143 on Bioelectronics Corp (BIEL)

[RVC]

Agree-company-not-obligated-just-irrational-to-not-PR-FDA-progress
However good business planning and investor support would benefit from confirming any FDA status change that would help to move the FDA process forward.

IE: Why did company allocate marketing expense to PR's regarding NHS....

Would seem irrational to PR NHS progress and not PR FDA progress.
Especially since we are talking about publicly available information.

http://www.bielcorp.com/bioelectronics-and-b-braun-medical-ltd-apply-for-prescription-payment-clearance-on-the-uk-drug-tariff/

-->FREDERICK, MD. Feb 18, 2016 — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer medical devices, announced today that B. Braun has initiated the application for a listing of RecoveryRx® on the National Health Service (NHS) drug tariff (http://www.nhsbsa.nhs.uk/PrescriptionServices/4940.aspx).The UK drug tariff list establishes payment for prescription costs in the UK.....<--